journal article·2026-03Open access

CD20 + FCRL4 + B Cells Activate CD8 + T Cells via MHC‐I Restriction in Nasopharyngeal Carcinoma Anti‐Tumor Immunity

Benjian Zhang, Xiaotian Yuan, Kelei Gao, Bo You, Yaxuan Wang, Lai Meng, Zirong Chen, Shaobing Xie, Yunqing Liu, Zijian Dong, Shumin Xie, Ruohao Fan, Fengjun Wang, Junyi Zhang, Zhihai Xie, Yongzhen Mo, Hua Zhang, Weihong Jiang

Advanced Science· Volume 13· Issue 13

Abstract

ABSTRACT Nasopharyngeal carcinoma (NPC) is a malignant tumor characterized by extensive immune cell infiltration. However, the function and significance of B cells in NPC have been overlooked. Exploring B cells and their interactions with other immune cells will provide deeper insights into the immune microenvironment of NPC and theories of immunotherapy.We utilized single‐cell sequencing data to identify characteristic B cell subtypes of NPC. Subsequently, the presence of the CD20 + FCRL4 + B cell subpopulation was validated in NPC samples using immunohistochemistry and flow cytometry. The interaction between this B cell subpopulation and CD8 + T cells was investigated by establishing an in vitro and in vivo co‐culture system.Our analysis revealed a subset of CD20 + FCRL4 + B cells that may interact with CD8 + T cells through the MHC‐I pathway. Furthermore, we observed a co‐localized distribution of CD20 + FCRL4 + B cells and CD8 + T cells in NPC. Additionally, in vitro experiments demonstrated that IFNγ played a pivotal role in enhancing the delivery of MHC class I‐restricted epitope peptides by B cells, potentially due to the upregulation of WDFY4. B cells pre‐stimulated with HK‐1 lysate and IFNγ, when co‐cultured with T cells, can induce the proliferation of CD8 + T cells and the formation of immunological memory. Ultimately, this process mediates the cytotoxicity of CD8 + T cells against tumor cells both in vitro and in vivo. Notably, we found a positive correlation between the infiltration level of CD20 + FCRL4 + B cells and the expression of PD‐1, as well as the response to anti‐PD‐1 therapy or gemcitabine plus cisplatin combined with anti‐PD‐1 therapy in NPC.Overall, our study elucidates the potential anti‐tumor mechanisms of CD20 + FCRL4 + B cells and provides insights into their role in immunotherapy for NPC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Immunotherapy and Biomarkers · Immunotherapy and Immune Responses · Immune Cell Function and Interaction

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Otolaryngology Head and Neck Surgery Xiangya Hospital of Central South University Changsha P. R. China

Hunan Province Key Laboratory of Otolaryngology Critical Diseases Xiangya Hospital of Central South University Changsha P. R. China

National Clinical Research Center for Geriatric Disorders Xiangya Hospital of Central South University Changsha P. R. China

Anatomy Laboratory of Division of Nose and Cranial Base Clinical Anatomy Center of Xiangya Hospital Central South University Changsha P. R. China

Department Of Head and Neck Surgery Guangxi Medical University Cancer Hospital Nanning Guangxi China

Institute of Otolaryngology Head and Neck Surgery Affiliated Hospital of Nantong University Nantong Jiangsu P. R. China

Department of Oncology Xiangya Third Hospital of Central South University Changsha P. R. China

School of Clinical Medicine Guizhou Medical University Guiyang Guizhou P. R. China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Hunan Province

References (56)

Show source-provided references
1. 10.1038/s41467-021-21795-z10.1038/s41467-021-21795-z ↗
2. 10.1016/S0140-6736(19)30956-010.1016/S0140-6736(19)30956-0 ↗
3. 10.1038/s41571-021-00524-x10.1038/s41571-021-00524-x ↗
4. 10.1002/cam4.391410.1002/cam4.3914 ↗
5. 10.1200/JCO.2017.77.038810.1200/JCO.2017.77.0388 ↗
6. 10.21037/cco.2016.04.0210.21037/cco.2016.04.02 ↗
7. 10.1177/1758835922109621410.1177/17588359221096214 ↗
8. 10.1016/S1470-2045(18)30495-910.1016/S1470-2045(18)30495-9 ↗
9. 10.1038/s41591-018-0096-510.1038/s41591-018-0096-5 ↗
10. 10.1016/j.cell.2018.11.04310.1016/j.cell.2018.11.043 ↗
11. 10.3389/fimmu.2022.101528310.3389/fimmu.2022.1015283 ↗
12. 10.1186/1476-4598-9-410.1186/1476-4598-9-4 ↗
13. 10.1002/ijc.3125210.1002/ijc.31252 ↗
14. 10.7150/jca.2.34110.7150/jca.2.341 ↗
15. 10.1016/j.bbcan.2021.18863210.1016/j.bbcan.2021.188632 ↗
16. 10.1016/j.cell.2017.10.04410.1016/j.cell.2017.10.044 ↗
17. 10.1016/j.immuni.2019.12.01210.1016/j.immuni.2019.12.012 ↗
18. 10.1016/j.trecan.2016.10.00910.1016/j.trecan.2016.10.009 ↗
19. 10.1016/j.celrep.2021.10959110.1016/j.celrep.2021.109591 ↗
20. 10.1038/s41586-020-03144-010.1038/s41586-020-03144-0 ↗
21. 10.1038/s41586-019-1914-810.1038/s41586-019-1914-8 ↗
22. 10.7150/thno.1896810.7150/thno.18968 ↗
23. 10.1016/j.cellimm.2012.01.00410.1016/j.cellimm.2012.01.004 ↗
24. 10.1038/s41591-023-02369-610.1038/s41591-023-02369-6 ↗
25. 10.1158/0008-5472.CAN-21-371410.1158/0008-5472.CAN-21-3714 ↗
26. 10.1158/2326-6066.CIR-20-094910.1158/2326-6066.CIR-20-0949 ↗
27. 10.1136/jitc-2020-00210110.1136/jitc-2020-002101 ↗
28. 10.1016/j.cell.2024.06.03810.1016/j.cell.2024.06.038 ↗
29. 10.1158/1078-0432.CCR-15-276210.1158/1078-0432.CCR-15-2762 ↗
30. 10.1016/j.cell.2021.11.00710.1016/j.cell.2021.11.007 ↗
31. 10.1182/blood.V99.9.331910.1182/blood.V99.9.3319 ↗
32. 10.3389/fcell.2021.67812710.3389/fcell.2021.678127 ↗
33. 10.1038/s41591-018-0057-z10.1038/s41591-018-0057-z ↗
34. 10.4049/jimmunol.200029310.4049/jimmunol.2000293 ↗
35. 10.1371/journal.pone.017979310.1371/journal.pone.0179793 ↗
36. 10.1155/2020/850980510.1155/2020/8509805 ↗
37. 10.1038/s41598-020-60811-y10.1038/s41598-020-60811-y ↗
38. 10.1158/1541-7786.MCR-19-054510.1158/1541-7786.MCR-19-0545 ↗
39. 10.1073/pnas.221995612010.1073/pnas.2219956120 ↗
40. 10.4049/jimmunol.180039910.4049/jimmunol.1800399 ↗
41. 10.1126/science.aat503010.1126/science.aat5030 ↗
42. 10.1016/bs.ai.2023.09.00210.1016/bs.ai.2023.09.002 ↗
43. 10.3390/cancers1507213310.3390/cancers15072133 ↗
44. 10.3389/fgene.2022.93574910.3389/fgene.2022.935749 ↗
45. 10.3389/fcell.2022.85713710.3389/fcell.2022.857137 ↗
46. 10.1038/s41422-020-0374-x10.1038/s41422-020-0374-x ↗
47. 10.1038/s41467-021-21043-410.1038/s41467-021-21043-4 ↗
48. 10.1186/s13073-023-01164-910.1186/s13073-023-01164-9 ↗
49. 10.1016/j.cell.2019.05.03110.1016/j.cell.2019.05.031 ↗
50. 10.1038/nbt.285910.1038/nbt.2859 ↗
51. 10.1126/science.aax024910.1126/science.aax0249 ↗
52. 10.1186/s12864-018-4772-010.1186/s12864-018-4772-0 ↗
53. 10.1038/s41467-021-21246-910.1038/s41467-021-21246-9 ↗
54. 10.1016/j.patter.2021.10029310.1016/j.patter.2021.100293 ↗
55. 10.1093/bioinformatics/btv63910.1093/bioinformatics/btv639 ↗
56. 10.1038/s41586-021-03819-210.1038/s41586-021-03819-2 ↗